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 CHAPTER 1 
INTRODUCTION 
Breast Cancer Statistics 
Breast cancer is the most common cancer among American women, second to skin 
cancers. The chance of developing invasive breast cancer at some time in a woman's life 
is about 1 in 8 (12%) and it is estimated that in 2008 about 182,460 new cases of invasive 
breast cancer (~67,770 new cases of non-invasive or carcinoma in situ (CIS)) will be 
diagnosed among women in the United States. Women living in North America have the 
highest rate of breast cancer in the world, and at this time there are about 2.5 million 
breast cancer survivors in the United States. Breast cancer is the second leading cause of 
cancer death in women, exceeded only by lung cancer. The chance that breast cancer will 
be responsible for a woman's death is about 1 in 35 (about 3%), and in 2008, about 
40,480 women will die from breast cancer in the United States. Death rates from breast 
cancer have been declining since about 1990, with larger decreases in women younger 
than 50. These decreases are believed to be the result of earlier detection through 
screening and increased awareness, as well as improved treatment (American Cancer 
Society, Inc. 2008).  
Background of Paralemmin 
Paralemmin is a phosphoprotein first identified in rat brain tissue where it is thought to 
play a role in the control of cell shape, plasma membrane dynamics, and cell motility 
(Kutzleb C, et al, 1998). Paralemmin is lipid-anchored to the cytoplasmic face of 
membranes through prenylation and di-palmitoylation (Figure 1.1) of a COOH-terminal 
cluster of three cysteine residues (Kutzleb C, et al, 2006). A possible role for paralemmin 
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as a SNARE molecule exists due to its predicted N-terminal coiled coil region, along 
with its palmitoylation and membrane association, which are reminiscent of SNARE 
molecule properties (Lane et al. 1997, Snyder et al. 2006 and Veit et al. 1996).  
Phosphorylation and mRNA splicing of paralemmin is tissue-specific and 
developmentally regulated and contributes to electrophoretic heterogeneity on Western 
Blots. Paralemmin is expected to interact and co-localize with specific partner molecules, 
such as certain integral membrane proteins and/or cytoskeletal proteins, possibly aiding 
as an adaptor or chaperone in their trafficking (Kutzleb C, et al, 1998). It has been shown 
that overexpression of paralemmin in fibroblast cells causes cell expansion and process 
formation with paralemmin concentrated at those sites (Kutzleb C, et al, 1998). Amino 
acids 154-230 of paralemmin, which correlate to exon 8 of the mRNA sequence, have 
been shown to interact with the third intracellular loop of the D3 dopamine receptor in 
the hippocampus and cerebellum in rat brain and in glial and neuronal cell cultures 
(Basile et al. 2005). In a more recent study, Arstikaitis and colleagues (2008) identified 
paralemmin as a regulator of filopodia induction, synapse formation and spine 
maturation. They also revealed an important role for paralemmin in recruitment of 
AMPA-type glutamate receptors, a process governed by alternative splicing of 
paralemmin.  Conversely, knockdown of paralemmin resulted in loss of filopodia and 
compromised spine maturation. Paralemmin is also differentially expressed in the 
developing mouse lens between model systems expressing different amounts of the 
transcription factor Pax6 (Chauhan et al. 2002 a, b).  
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Discovery of Paralemmin in Breast Cancer 
A cDNA microarray comparison between the estrogen receptor (ER)-positive, MCF-7 
breast cancer cell line and the tamoxifen-selected ER-negative, TMX2-28 breast cancer 
cell line indicated that paralemmin was more highly expressed in the aggressive and 
invasive ER-negative TMX2-28 cells (Gozgit 2006). This led us to the initial hypothesis 
that paralemmin would be more highly expressed in cell lines and tissues which were ER 
negative and aggressive. To verify these findings we used qRT-PCR and determined that 
paralemmin mRNA is expressed ~8-fold higher in TMX2-28 cells as compared to MCF-7 
cells and is almost undetectable in non-tumorigenic breast cell lines including MCF-10A, 
184, 184A1 and 184AA2. Also, paralemmin was expressed at low levels in MDA-MB-
231 cells, which are ER negative, highly invasive and aggressive, and display a 
fibroblastic-like morphology and mode of invasion (Gozgit 2006).  
 
To determine whether paralemmin is expressed in human breast cancer tissues, mRNA 
expression was evaluated in thirty frozen human breast tumor specimens. Paralemmin 
was expressed at various levels (from 0.0076 to 1.17 relative units, normalized to HPRT) 
among the thirty samples and showed relatively higher levels (>0.5 relative units) in 
roughly 30% of the tissues examined.  Of the 30% showing higher levels of expression 7 
out of 9 of the tumors were ER positive.  
 
Paralemmin protein expression was evaluated in human breast cancer and normal tissue 
specimens using a crude serum and a control crude preimmune serum received from Dr. 
Manfred Kilimann, Uppsala University, Sweden (Gozgit 2006). He began by examining 
paralemmin protein expression in one tumor specimen (number 14), which had higher 
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mRNA levels of paralemmin. Tumor 14 had positive immunoreactivity for paralemmin 
and, as hypothesized, the expression of paralemmin was localized to the plasma 
membrane.  Next, paralemmin protein expression and localization was examined in tissue 
microarrays prepared from a small set of breast cancers. Paralemmin was overexpressed 
in 15 of 33 human breast carcinomas and in all cases was significantly localized to the 
plasma membrane. Moreover, there was a trend for greater paralemmin staining in tumors 
that expressed the estrogen receptor. Finally, he determined that paralemmin protein was 
highly expressed in 5 of 11 reduction mammoplast tissues by tissue microarray analysis 
(Gozgit 2006). These preliminary data formed the basis of the present work in which I 
have expanded on the characterization of paralemmin’s protein and mRNA expression in 
breast cell lines and tumor tissue. Additionally, through the analysis of several breast 
cancer and reduction mammoplasty tissue microarrays, I have examined the cellular 
localization and expression of paralemmin in both diseased and normal tissue. Finally, I 
have described the exon splice variant patterns in cell culture, tumor tissue and reduction 
mammoplasty tissue. 
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Paralemmin is prenylated and di-palmitoylated at its C-terminus 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  Prenylation and di-palmitoylation of paralemmin. 
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CHAPTER 2 
PARALEMMIN'S PROTEIN AND MRNA IS DIFFERENTIALLY EXPRESSED 
IN BREAST CANCER AND NON-TUMORIGENIC CELLS 
Introduction 
 
After the initial discovery that paralemmin was differentially expressed between two 
breast cancer cell lines (TMX2-28 and MCF-7), by cDNA microarray, it was our next 
step to focus on differences in mRNA expression by qRT-PCR and differences in protein 
expression by Western Blot. Paralemmin mRNA has previously been shown to be 
differentially expressed among various tissues in chicken, human, mouse and fibroblast 
and neuroblastoma cells (Kutzleb et al. 1998).  The electrophoretic heterogeneity of 
paralemmin protein (detected as multiple bands on Western Blots) has also been shown, 
as has variability of expression among different tissues in mouse and between fibroblast 
and neuroblastoma cells. It was then important to determine whether there were 
differences in expression of paralemmin mRNA and protein between breast cancer and 
non-tumorigenic breast cell lines, and whether we would see multiple bands on Western 
Blots when analyzing the cellular protein from these same cell lines. If there is a 
relationship between mRNA expression and protein immunoreactivity patterns with 
important parameters such as ER status and invasiveness of the cells, then this will allow 
us to begin to understand a possible function of paralemmin in breast cancer. Because the 
cDNA microarray compared only two cell lines, it was important to test multiple breast 
cancer cell lines and a few “non-tumor derived” cell lines (Table 2.1).  This will give us a 
clearer understanding into a possible role for paralemmin in breast cancer, and will allow 
us to better explain its expression profile. 
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Materials and Methods 
Cell Culture and RNA Purification 
TMX2-28 cells were kindly provided by Dr. John Gierthy (Wadsworth Center, Albany, 
NY). MCF-7 cells were purchased from the American Type Culture Collection 
(Manassas, VA), and 184, 184A1, and 184AA2 cell lines were generous gifts from Dr. 
Martha Stampfer (Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, 
CA). HMECs were purchased from Clonetics (East Rutherford, NJ) whereas MDA-MB-
231, BT20, T47D, ZR75, and MCF-10A were obtained from the Wadsworth Center 
frozen stocks. TMX2-28 and MCF-7 cells were grown in DMEM (without phenol red) 
supplemented with 5% cosmic calf serum (Hyclone, Logan, UT), 2.0 mmol/L of L-
glutamine, 0.1 mmol/L of nonessential amino acids, 10 ng/mL of insulin, 100 units/mL of 
penicillin, and 100 µg/mL of streptomycin (referred to as DC5). T47D, ZR75, BT-20 and 
MDA-MB-231 cells were maintained in complete growth medium, which includes 10% 
FBS according to the American Type Culture Collection protocol. HMECs and MCF-
10A were grown in mammary epithelial growth medium (Clonetics) which contains 
growth factors but no serum, whereas 184, 184A1, and 184AA2 were cultured in 
mammary epithelial growth medium according to Dr. M. Stampfer’s protocol as posted 
on her website (http:// www.lbl.gov/LBL-Programs/mrgs/). Cells were maintained in a 
humidified incubator at 37°C with 5% CO2. RNA was isolated from cell cultures with 
TRI Reagent (Molecular Research, Cincinnati, OH) according to the manufacturer’s 
protocol. Isolated RNA was further purified using the Qiagen RNeasy kit with on-column 
DNase digestion (Qiagen, Valencia, CA). 
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Protein Isolation and Western Immunoblotting 
Cell cultures were lysed with pre-chilled SDS buffer (1% SDS and 0.06 mol/L Tris-HCl), 
and cell extracts were used for Western immunoblotting. Protein lysates (15 µg) were 
mixed with NuPage sample buffer and reducing agent (Invitrogen, Carlsbad, CA), and 
then heated at 70°C for 10 min. Protein lysates were then separated on a 10% Tris-HCl 
polyacrylamide gel (Bio-Rad, Hercules, CA) using the Min-Protein 3 cell (Bio-Rad) 
according to the manufacturer’s protocol. Separated proteins were transferred to an 
Immuno-Blot polyvinylidene difluoride membrane (Bio-Rad) using the Mini Trans-Blot 
electrophoretic transfer cell and protocol (Bio-Rad). Membranes were incubated in 
blocking buffer (5% nonfat dry milk/TBS and 0.1% Tween 20) for 30 min at room 
temperature with gentle shaking. The membrane was then incubated with the primary 
antibody overnight at 4°C, and with the appropriate secondary antibodies, either anti-
rabbit IgG horseradish peroxidase–linked antibodies (1:1,000, Cell Signaling 
Technology, Beverly, MA) or anti-mouse IgG horseradish peroxidase–linked antibodies 
(1:5,000, Santa Cruz Biotechnology, Santa Cruz, CA), for 1 h at room temperature. 
Chemiluminescent signals were detected with the SuperSignal West Pico kit and protocol 
(Pierce, Rockford, IL). Anti-paralemmin rabbit polyclonal antibody (15) was diluted 
1:75,000 for Western immunoblotting, and β-actin 1:1,000 (Cell Signaling Technology).  
Membranes were imaged using the G:BOX Chemi HR-16 (Syngene). 
 
Quantitative Real-Time PCR 
Quantitative Real-Time PCR was done as previously described (Gozgit et al. 2006). RNA 
samples were reverse transcribed and amplified using the One-Step RT-PCR kit (Qiagen) 
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in the Roche Light Cycler. Total RNA (75 ng) was incubated with Qiagen RT-PCR 
master mix including primers (25 µmol/L each) and SYBR Green I nucleic acid stain 
(diluted 1:5,000; Molecular Probes, Eugene, OR) in pre-cooled capillaries (Roche) and 
was reverse transcribed. Following reverse transcription, samples were heated, to activate 
the HotStar Taq DNA polymerase and to simultaneously inactivate the reverse 
transcriptase. The generation of amplified products was monitored over 45 PCR cycles 
by fluorescence of intercalating SYBR Green. Relative mRNA levels were normalized to 
hypoxanthine ribosyltransferase (HPRT) levels to control for RNA quality and 
concentration (de Kok, J. B., R. W. Roelofs, et al. (2005)). The following gene-specific 
primers were designed using Primer3: HPRT NM_000194: 
ACCCCACGAAGTGTTGGATA (nucleotide 587, sense), 
AAGCAGATGGCCACAGAACT (nucleotide 834, antisense); Paralemmin NM_002579: 
GAGTGAGCCACTCCTTGTCC (sense, nt 2057), GTGCTCCAAGCCCAGTAGAG 
(antisense, nt 2241). 
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Results and Discussion 
Paralemmin mRNA Expression 
 
Quantitative reverse transcription PCR (qRT-PCR) was run on mRNA isolated from both 
cancer and non-tumorigenic breast cell lines (Figure 2.3). There is a large difference 
between the ER-neg and invasive TMX2-28 cell line and the ER-pos, non-invasive MCF-
7 parent cell line mRNA expression. The second highest ER-neg cell line for paralemmin 
expression is MDA-MB-321 which is invasive, but all other ER-neg cell line’s 
expressions are below the readable levels. Paralemmin mRNA expression is highest in 
ZR-75-1 cells which are both an ER-pos and non-invasive cell line. There is little to no 
expression of paralemmin mRNA in BT-20, MCF-10A or HMEC cells. It was our initial 
thought that paralemmin would be more highly expressed in ER-neg and aggressive cell 
lines (by looking at cDNA microarray data only), but when looking at either ER status or 
the invasive properties of the cells, no correlation exists to paralemmin expression levels. 
 
Paralemmin’s Protein Expression Profile in Breast Cell Lines 
Examination of cellular protein by Western Blot analysis, using paralemmin crude 
primary antibody, reveals that paralemmin protein is differentially expressed among 
breast cancer and non-tumorigenic cell lines and that there are multiple bands 
(electrophoretic heterogeneity) (Figure 2.1). We also see that the electrophoretic mobility 
of the bands differs between cell lines. Protein sequence data show that paralemmin is a 
42kDa protein, but this is not reflected by immunoblot analysis, as the major bands are at 
~70kDa and 60kDa. The banding patterns from the TMX2-28 cellular protein and the 
MCF-7 cellular protein are almost identical with one band just below 60kDa and another 
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at ~70kDa (although paralemmin mRNA has been shown to be more highly expressed in 
TMX2-28 cells as compared to MCF-7 cells). Relative quantification values of bands 
(Figure 2.4) from TMX2-28 and MCF-7 are roughly 2 to 3 units apart.  The differences 
between mRNA and protein expression could be due to a higher efficiency for MCF-7 
cells to translate paralemmin protein. The same two bands are also seen in the ZR-75-1 
lane, with the difference being a higher intensity in the ZR-75-1, 60kDa and ~70kDa 
bands (68.7 units for the 70kDa band compared to 52.8 units for the same band in MCF-
7, and 111.9 units for the 60kDa band compared to 44.5 units for TMX2-28). For the 
MDA-MB-231 and T47D lanes, we see a doublet with the top band at ~70kDa, which is 
the same band as in the TMX2-28, MCF-7 and ZR-75-1 lanes, and a new band just below 
that band at ~65kDa. The MCF-10A has its upper bands at 70kDa and 60kDa similar to 
TMX2-28, MCF-7 and ZR-75-1, but also has a band at 35kDa. The 184 and 184AA2 
lanes both have the lower band of the doublet seen in MDA-MB-231 and T47D, and the 
184A1 has only the band at 70kDa. MCF-10A, 184, 184A1 and 184A2 lanes have a band 
that shows up around the 35kDa area. It is possible that this band could be non-specific, 
since no known splice variant or post transcriptional modification is known to occur 
which could account for this band. These results indicate that paralemmin protein may go 
through different post transcriptional modification steps depending on the cell line. Some 
possible explanations for these multiple bands could be differences in phosphorylation, 
different splicing events taking place or possible differences in lipidation modifications. 
Multiple phosphorylation sites add to the acidic nature of the protein, and cause the 
protein to migrate more slowly than its size should dictate. The major difference between 
cancer cell and non-tumorigenic cell expression is that in the cancer cells, there are two 
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major bands at 60kDa and 70kDa, and in the non-tumorigenic lines either the upper band 
is present or the lower band of the doublet present. There is also the presence of the band 
at 35kDa in the non-tumorigenic lines that is not present in the cancer lines, but this may 
be a protein that is present in the non-tumorigenic lines that is reacting non-specifically to 
the crude antibody, since there are no known splice variants or post transcriptional 
modifications which could account for a product of this size. There is no apparent 
correlation between paralemmin protein expression and parameters such as ER status and 
invasiveness of the cell lines. 
 
As a control to ensure that the crude antibody used was not reacting with other non-
specific proteins, a pre-immune serum was also analyzed on the same membranes for 
immunoreactivity (Figure 2.2).  For most cell lines, all but TMX2-28 and MCF10A, there 
is a band at ~50kDa.  When comparing the two images, it is clear that this band does not 
contribute to any of the bands observed when using crude antibody. There is another 
band that is seen in the 184A1 lane at ~35kDa using the pre-immune serum, that is in the 
same location as seen using the crude serum in MCF-10A, 184, 184A1 and 184AA2 
lanes. This band appears when either the crude antibody or the pre-immune serum is 
applied and should not be considered to be reacting exclusively with paralemmin protein 
but rather an artifact of the antibody generation.  
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Conclusion 
In this chapter, we have examined paralemmin mRNA and protein expression among 
breast cell lines. Analysis of paralemmin protein by Western Blots identified multiple 
bands that are cell line specific, which is consistent with previous paralemmin protein 
analysis (Kutzleb et al. 1998), and that expression varies between cell lines. This is 
reminiscent of a similar membrane phosphoprotein, GAP-43, that also exhibits different 
electrophoretic mobilities (Stricker et al. 2006). We also see that the specific banding 
patterns differ between both breast cancer cell lines and non-tumorigenic cell lines tested. 
This phenomenon is likely due to the pre and post translational modification events 
experienced by paralemmin such as differential splicing, phosphorylation of the protein 
and lipidation of the protein by prenylation and palmitoylation. Paralemmin mRNA 
expression also varies among the breast cell lines examined, cancer and non-tumorigenic. 
Interestingly, paralemmin is highly expressed in TMX2-28 and ZR-75-1 cell lines, and is 
almost undetectable in MCF-7, T47D, BT-20 and the non-tumorigenic cell lines MCF-
10A, 184, 184A1 and 184AA2. There is no clear correlation between paralemmin 
expression and ER status or invasiveness of the cell lines tested, as it is most highly 
expressed in ZR-75-1 cells which are ER-pos and non-invasive and the next highest 
expression in TMX2-28 (~12x less than ZR-75-1) and MDA-MB-231 (~6x less than 
TMX2-28) cells which are ER-neg and invasive.  Because paralemmin is a membrane 
protein that has been shown to cause process formation and cell expansion (Kutzleb et al. 
1998, 2006, Arstikaitis et al. 2007), further study is warranted to determine if knockdown 
or overexpression of paralemmin would cause cells to become more/less invasive. 
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Cell Line  Origin  Age Pathology ER  Cell Type Invasive 
MCF-7 Pleural 
effusion  
69 IDC Pos Luminal No 
BT-20 Breast 74 IDC Neg1 Luminal Yes (cl) 
T47D Pleural 
effusion 
54 IDC Pos Luminal No 
ZR-75-1 Ascites 47 IDC Pos Luminal No 
MDA-MB-
231 
Pleural 
effusion 
51 Adeno Neg Mesenchymal Yes (s) 
MCF-10A Breast 36 N.R Neg Luminal No 
1842 Reduction 
mammoplasty 
15-
66 
N.R. Neg Basal No 
184A13 Reduction 
mammoplasty 
15-
66 
N.R. Neg Basal No 
184AA23 Reduction 
mammoplasty 
15-
66 
N.R. Neg Basal No 
TMX2-284 Pleural 
effusion 
69 IDC Neg Basal/ 
Luminal 
Yes 
 
Table 2.1  Human Breast Cell Lines 
1: BT-20 cells express ER mRNA, but do not express ER protein 
2: Non-tumorigenic mammary cell line from Martha Stamfer’s Laboratory 
3: Derivative of 184 cells 
4: Derivative of MCF-7 cells 
Invasion: (cl) = invades in clusters of cells, (s) = single cells invade 
IDC: Invasive ductal carcinomas 
Adeno: Adenocarcinoma 
N.R.: 
Sources: Burdall et al., 2003, Lacroix and Leclercq, 2004, Tong et al. 1999, 
http://www.lbl.gov/LBL-Programs/mrgs/ 
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Figure 2.1  Paralemmin mRNA expression among breast cell lines.   
Cell cultures were grown to confluence, total RNA was isolated and cleaned up, and 
paralemmin mRNA expression was determined by qRT-PCR.  Data are normalized to 
HPRT, and are representative of three separate runs; SD represents variation between 
PCR experiments. 
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Western Blot Analysis Using Paralemmin Crude Antibody 
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Figure 2.2  Paralemmin crude antibody Western immunoblot. 
Cell cultures were grown to confluence, protein was isolated and paralemmin protein 
expression was determined by western immunoblotting. 184 lane is from previous 
western immunoblot. β-actin was used as a loading control. 
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Western Blot Analysis Using Paralemmin Pre-immune Serum 
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Figure 2.3  Paralemmin pre-immune serum control Western immunoblot. 
Cell cultures were grown to confluence, protein was isolated and paralemmin protein 
expression was determined by western immunoblotting. 184 lane is from previous 
western immunoblot.  β-actin was used as a loading control. 
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Figure 2.4  Relative quantification of paralemmin Western Blot bands  
Western Blot images taken on G:BOX Chemi HR-16 were quantified by histogram 
analysis using Photoshop for band intensity. Average (of 2) values displayed are minus 
an average background measurement taken at five different locations. 
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CHAPTER 3 
EXAMINING PARALEMMIN MRNA BY QRT-PCR AND PROTEIN 
EXPRESSIN AND LOCALIZATION BY TISSUE MICROARRAY IN 
REDUCTION MAMMOPLASTY AND BREAST TUMOR TISSUE 
Introduction 
 
Since we are the first to examine paralemmin as a potential biomarker in breast cancer, it 
is necessary to observe its expression and cellular localization in a range of breast cancer 
tumors from different stages of cancer progression. The paralemmin gene was found to 
be differentially expressed between two cancer cell lines, TMX2-28 and MCF-7, by 
cDNA microarray (Gozgit 2006). To verify this data, paralemmin expression has been 
quantified in normal and cancer cell lines, and has been found to be differentially 
expressed among the cancer cell lines. Interestingly, paralemmin was found to be highly 
expressed in some cancer cell lines (TMX2-28, ZR-75-1), with little to no expression in 
the non-tumorigenic cell lines tested (MCF-10A, 184). Here I examine mRNA extracted 
from frozen breast tumor and reduction mammoplasty tissue for paralemmin expression. 
This allows me to look at paralemmin expression in cancer tissue with known pathology 
and compare that to expression in a more normal tissue by qRT-PCR. With these data, we 
will be able to show whether or not there is a correlation between paralemmin expression 
and important breast cancer characteristics such as estrogen receptor status and the 
invasive property of the tumor.  
 
Next, using a technique previously described by Kononen et al. (1998), tissue 
microarrays (TMAs) were constructed to explore the expression of paralemmin protein in 
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breast cancer tissues and tissues obtained from reduction mammoplasty. For this study, I 
examined 40 reduction mammoplast tissues, 31 ductile carcinoma in-situ (DCIS) cases 
and 65 infiltrating ductile carcinoma (IDC) cases for paralemmin expression and 
localization. Looking at these two types of carcinomas (DCIS and IDC) gives insight into 
cancers at two distinct stages of progression, while the tissue from reduction 
mammoplasty allows inspection of a more “normal” type of tissue. From the data 
obtained by interpretation of multiple TMAs through immunohistochemistry (IHC), 
examining paralemmin expression and localization among these different tissue types, I 
will understand any correlations between differences in expression to a tumor type at a 
specific stage of cancer development. If paralemmin is associated with a specific stage of 
cancer progression, it is possible to then explore the use of paralemmin as a potential 
therapeutic target in a subset of breast cancers. Pathological reports on all cases were 
obtained and used to further characterize paralemmin’s expression to tumor types. 
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Materials and Methods 
 
 
Quantitative Real-Time PCR 
As previously described in Chapter 2. 
 
RNA From Human Tissue Specimens 
Twenty six breast tumors were retrieved from Baystate Medical Center, Department of 
Surgical Pathology and were identified numerically, maintaining patient anonymity 
(Gozgit 2006). Institutional Review Board approval for this study was obtained from 
Baystate Medical Center. The tissue specimens were sectioned to ≤0.5 cm in thickness 
and immediately placed in pre-chilled RNA Later-Ice (Ambion, Austin, TX) for 24 
hours. Tissues (20-30 mg) were homogenized and RNA was isolated using the Qiagen 
RNeasy Fibrous Tissue kit (Qiagen) (Gozgit et al. 2006).  Reduction Mammoplasty RNA 
was a generous gift from Dr. Sallie Smith-Schneider (Pioneer Valley Life Science 
Institute, Springfield, MA). 
 
Tissue Specimens, Tissue Microarray and Immunohistochemistry 
All tissue (FFPE breast tumors, n = 91; and FFPE reduction mammoplasty tissue, n = 40) 
were retrieved from Baystate Medical Center, Department of Surgical Pathology and 
were identified numerically, maintaining patient anonymity. Institutional Review Board 
approval for this study was obtained from Baystate Medical Center. The 91 breast tumor 
samples were from primary breast carcinomas. TMAs were constructed by extracting 
three 1.0-mm diameter cores from each breast tumor donor FFPE block and re-
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embedding them into a recipient paraffin block containing pre-extracted holes in paraffin 
spaced 2.0 mm apart.  Previously scored cases for paralemmin (Gozgit JM. 2006) ranging 
from 0 to 3+ (staining intensity) were inserted into each block as controls. Four-
micrometer sections were placed on charged slides, deparaffinized in xylene, and 
rehydrated in graded ethanols. Slides were rinsed in water and incubated in Citra Plus 
Buffer (BioGenex, San Ramon, CA) under the following conditions for antigen retrieval: 
micro waving for 3 min, cooling for 1 min, heating at 98°C for 10 min, and cooling for 
20 min. Immunohistochemistry was done on the Dako Autostainer using Dako Envision 
Plus labeled polymer horseradish peroxidase reagents. Anti-Paralemmin rabbit 
monoclonal antibody was diluted 1:5,000 for immunohistochemistry (Gozgit JM. 2006). 
The immunoreactivity of paralemmin was scored by a pathologist (C.N. Otis) for the 
intensity and the percentage of positive cells. Immunohistochemistry sections were 
scored on a numerical basis for both staining intensity [ranging from 0 (not discernible) 
to 4 (darkest staining among all controls and cases)] and the percentage of positive cells 
where 0, no staining; 1, <25%; 2, 25% to 50%; and 3, >75%. The score for staining 
intensity was multiplied by the score for the percentage of positive cells and the products 
were separated into four groups: no staining, weak, moderate, and strong staining.  
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Results and Discussion 
Paralemmin mRNA Expression 
Paralemmin mRNA expression varied among the 26 breast tumor tissue samples (Figure 
3.1). ER expression was determined by pathology reports (Gozgit 2006). The expression 
values were ranked from lowest to highest, and the bars on the graph colored red/lined for 
ER-positive samples or black for ER-negative samples. An arbitrary expression level of 
>0.5 arbitrary units was set to define a higher level of paralemmin expression. Among the 
samples designated to have high paralemmin expression (relative units >0.5), 12 of the 14 
are ER-positive (86%). These data suggest that a higher expression level of paralemmin 
mRNA may be associated more closely with tumors that express the estrogen receptor. 
Being that ER expression has been one of the most important clinical diagnostic 
parameters for describing breast cancer for the past thirty years, this may be an important 
relationship to more closely observe. 
 
We also examined paralemmin mRNA expression in tissue obtained from reduction 
mammoplasty, and once again found much variation among samples (Figure 3.2).  
Interestingly, the expression levels were much higher (for many cases over 20x higher) 
than those from cell lines or from breast tumor tissue. One explanation for the vast 
difference in expression may be that tissue obtained from reduction mammoplasty has a 
higher proportion of adipose tissue cells, whereas tissues from breast tumors contain a 
higher proportion of epithelial cells. 
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Tissue Microarrays 
40 reduction mammoplasty (RM) cases, 31 ductile carcinoma in-situ (DCIS) cases and 65 
infiltrating ductile carcinoma (IDC) cases were arranged onto tissue microarrays (TMAs), 
sliced, put onto slides and stained with paralemmin crude antibody at 1:5000. Two slides 
were stained for each TMA block to ensure we had good samples for scoring. The arrays 
were scored on separate days by two pathologists at Baystate Medical Center, 
Springfield, MA. Each pathologist scored both slides (1 and 2) from each TMA (Turk-1 
and Turk-2 (RM), Turk-6(DCIS), Turk-4 and Turk-7 (IDC)), and these scores were 
arranged and given a value of 0, 1+, 2+ or 3+. For each case, I used the highest score 
given to any of the three punches for each specific case. In analyzing the data, I assigned 
a value of weak or strong to every case (0 and 1+ being weak, 2+ and 3+ being strong), 
and arranged the data into tables. If a particular case was scored as having an in-situ and 
an invasive component, I only used the in-situ score for DCIS TMA cases or the invasive 
score for IDC TMA cases, and counted the in-situ and invasive components as separate 
entities. For all cases, paralemmin staining was highly membranous. 
 
First I wanted to compare overall weak to strong paralemmin staining among the RM, 
DCIS and IDC TMAs (Table 3.1). Of the 40 RM cases scored, 29 (73%) were scored as 
weak while 11 (27%) were scored as strong.  Conversely, both the DCIS and IDC TMAs 
had a higher number of strong staining cases than weak staining cases. On the DCIS 
TMA, 7 of the 31 (23%) cases were scored as weak while 24 of the 31 (77%) cases were 
scored as strong, and for the IDC TMAs, 20 of the 65 (31%) were scored as weak and 45 
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of the 65 (69%) were scored as strong. Interestingly, a shift is seen from a higher 
proportion of weak staining in the RM cases to a higher amount of strong staining in both 
the DCIS and IDC cases. These data suggest that paralemmin is more highly expressed in 
cancer tissue than in non-tumorigenic tissue. When comparing paralemmin staining 
between the DCIS and IDC cases, we see that the proportions of weak to strong staining 
are relatively the same, and the slight difference could be due to a larger number of IDC 
cases examined than DCIS cases. 
 
We next examined the TMA scoring data to see if there was a correlation between 
paralemmin staining and tumor grade. As tumor grade has been shown to be a strong 
predictor of outcome in patients with invasive breast cancer (Rakha et al. 2008 and Elston 
2005), I wanted to investigate a possible connection between paralemmin staining and 
tumor grade. Because a number of the DCIS cases were associated with IDC, I made 
separate comparisons for the DCIS TMA and the IDC TMAs. For the DCIS TMA I 
compared the tumor grade to the paralemmin score for the in-situ component of the 
tumor, and for IDC TMAs, I compared rumor grade to only the invasive component 
paralemmin score (Table 3.2 A and B). When examining the DCIS TMA, 2 of the 8 cases 
that are grade I (25%), 5 of the 14 cases that are grade II (36%) and 2 of the 12 cases that 
are grade III (17%) were weakly stained, and 6 of 8 grade I cases (75%), 9 of 14 grade II 
cases (64%) and 10 of 12 grade III cases (83%) were scored as strong for paralemmin 
(Table 3.2A). For all three tumor grades, a higher proportion of cases highly express 
paralemmin, with the grade III tumors having the highest percentage. When comparing 
paralemmin staining to tumor grade in IDC cases, there is a slight difference. The grade I 
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tumors have almost equal amounts of weakly and strongly stained cases (6 and 7 
respectively) (Table 3.2B). The grade II and III cases are similar to the DCIS ratios with 
grade II having 5 of 20 cases (25%) weakly positive for paralemmin and 15 of 20 cases 
(75%) strongly positive, and with grade III having 11 of 33 cases (33%) weakly positive 
and 22 of 33 cases (67%) strongly positive for paralemmin. Apart from the grade I IDC 
cases, there is a general trend towards higher paralemmin expression in all cancer cases 
examined thus far, as is seen in Table 3.1. A more even weak to strong ratio of staining in 
the grade I IDC cases suggests that paralemmin is weakly expressed more often in grade I 
cancers.  
 
Finally, we examined the relationship between paralemmin staining and hormone 
receptor (ER and PR) and HER-2 status. ER, PR and HER-2 are some of the oldest and 
most useful predictive biomarkers in breast cancer, and have become standard 
measurements in the management of breast cancer patients (Faratian et al. 2008 and 
Payne et al. 2008). For this reason I found it important to test whether paralemmin 
expression was correlated to the presence or absence of one or all of these biomarkers. 
For this evaluation a HER-2 score of 0 or 1+ was called a negative and a score of 2+ or 
3+ was called positive.  
 
When comparing paralemmin staining to ER status, 21 of the 81 ER positive cases (26%) 
were weakly stained and 60 of the 81 cases (74%) displayed a strong staining (Table 3.3). 
For the ER negative cases, 8 of the 14 cases (57%) were scored as weak and 6 of the 14 
(43%) as strong. Although there are far fewer ER negative cases, it is apparent that 
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paralemmin is highly expressed in ER positive tumors compared to ER negative tumors 
where a weaker staining pattern emerges. PR status was next examined with similar 
results. 16 of the 70 PR positive cases (23%) stained weak for paralemmin while 54 of 70 
(77%) stained strong. The PR negative cases were closer to being even as 12 of 25 cases 
(48%) stained weak and 13 of 25 (52%) stained strong for paralemmin. It should be noted 
that a majority of the PR negative cases are also ER negative, which could be an 
explanation as to why they are closely related in percentages. We see a similar pattern, 
low percentage of weak staining to a higher percentage of strong staining when we 
compare HER-2 status to paralemmin staining. For the HER-2 positive cases, 7 of 24 
(29%) were scored as weak and 17 of 24 (71%) scored as strong, and for HER-2 negative 
cases, 20 of 67 (30%) scored as weak and 47 of 67 (70%) were scored as strong for 
paralemmin (Table 3.3). This follows a pattern similar to overall staining for paralemmin, 
comparing weak to strong staining for both DCIS and IDC cases. Of the 11 triple 
negative cases in the arrays, 5 were scored as weak and 6 as strong for paralemmin which 
does not follow the overall (roughly 30% to 70% weak to strong) staining pattern for the 
cases examined. This relationship seems to be more due to the ER/PR negative cases than 
to the HER-2 negative cases. 
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Conclusion 
In the evaluation of breast tumor tissue mRNA for paralemmin expression by qRT-PCR, 
we have found differential expression of paralemmin among the samples. When the 
tumor samples were separated based on ER status, we found that paralemmin was more 
highly expressed in those tissues expressing the estrogen receptor. In fact, 14 of the 16 
(88%) samples that had expression levels greater than 0.5 relative expression units were 
ER positive breast tumors and 9 of the 12 (75%) samples where expression levels were 
less than 0.5 relative expression units were ER negative. Performing a Mann-Whitney U 
test on the data confirms that paralemmin is significantly more highly expressed in ER-
pos tumors.  Although, this goes against our initial hypothesis that paralemmin would be 
more highly expressed in ER negative and aggressive tumors, due to a possible role for 
paralemmin in cell expansion and process formation (Kutzleb et al. 1998 and Arstikaitis 
et al. 2008), it fits with previous data which shows paralemmin to be more highly 
expressed in ER positive tumors (Gozgit 2006). 
 
I next compared paralemmin expression in tumor tissue to expression in tissue obtained 
from reduction mammoplasty tissue. qRT-PCR was performed on reduction 
mammoplasty RNA obtained from Dr. Sallie Schneider-Smith. Interestingly, I found that 
paralemmin expression in reduction mammoplast tissue was higher when compared to 
both cell line and tumor tissue expression. Previous work by Tripathi et al. (2008) has 
shown, by cDNA microarray analysis, that gene expression profiles of reduction 
mammoplasty tissue and normal tissue adjacent to cancer tissue (histologically normal 
breast epithelium) to significantly differ in 127 probesets, and that most of these 
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differences remained when comparing reduction mammoplast tissue to DCIS tissue gene 
expression profiles. This leaves much to be explored as to, what is reduction mammoplast 
tissue, and why there is so much growth in these tissues. It would be interesting to have 
tissue samples taken from women during breast enhancement, or other procedures not 
associated with reduction, to examine against reduction mammoplast tissue. This may 
give insight as to differences between these two phenomenon. 
 
The construction of tissue microarrays has become a valuable asset when evaluating 
multiple tissue samples with different or similar characteristics at the same time. The use 
of an array lessens the chances for variance in antigen retrieval and antibody staining due 
to all cases being subjected to the same processes all at the same times. The methods used 
to construct and evaluate tissue microarrays have been validated on numerous occasions 
and have been proven to be reliable (Emerson et al. 2006, Leversha et al. 2003, Packeisen 
et al. 2002, Camp et al. 2000 and Kononen et al. 1998). For this analysis, I constructed 
three types of tissue microarrays; one made of reduction mammoplasty cases (RM), one 
made of ductile carcinoma in-situ cases (DCIS) and another made of infiltrating ductile 
carcinoma cases (IDC). These represent three different types of tissue and cancers from 
two distinct stages of progression. My goal was to evaluate these arrays for the 
expression of paralemmin and investigate whether there were any correlations between 
paralemmin staining and the type of tissue examined. When comparing overall staining 
among the three types of tissues, one observable difference emerged. While the two 
cancer arrays (DCIS and IDC) maintained a staining pattern of ~30% weak and ~70% 
strong, the RM array had just the opposite staining 73% strong for paralemmin and 28% 
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weak. Performing Chi square analysis confirms that paralemmin is expressed differently 
in the reduction mammoplast cases than in DCIS or IDC cases. This leads to the 
conclusion that as tissue progresses from a more normal to a cancerous morphology, 
paralemmin is more highly expressed throughout the tissue. The results from qRT-PCR 
differ from these results, as qRT-PCR revealed high paralemmin expression in RM tissue 
while paralemmin staining intensity was low in RM tissue for IHC. These differences 
could arise because in IHC, we only score the epithelial cells and the RNA isolated from 
RM tissue is representative of all cell types. A similar pattern emerged when comparing 
paralemmin expression to the specific grade of the tumors. This pattern was observed 
more obviously in the IDC cases where we see an increase in the strong to weak ratio as 
tumors progress from grade I to grade III tumors. This would suggest that as tumors 
progress from grade I to grade III, paralemmin becomes highly expressed. When 
comparing paralemmin expression to HER-2 status, a similar pattern is observed as in 
overall expression among DCIS and IDC cases, and thus no correlation was observed. In 
the case of ER/PR status, we find something interesting. In both ER and PR positive 
cases, a similar staining pattern emerged as in overall staining, but when we examine the 
ER and PR negative cases a trend towards weak staining is observed, which was also 
seen when I examined paralemmin expression by qRT-PCR. For the ER negative cases, 
57% stained weak for paralemmin, and in the PR negative cases, 48% stained weak for 
paralemmin. Similarly, this was also observed when examining tumor tissue by qRT-
PCR, where a greater percentage of the tissues examined, expressing high levels of 
paralemmin, were ER positive (Figure 3.1).  
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Figure 3.1  Paralemmin expression in breast tumor tissue. 
Total RNA was isolated from frozen breast tumors and gene expression for paralemmin 
was determined by qRT-PCR analysis.  Tumors were sorted by paralemmin mRNA 
expression and ER-positive sample bars were colored red.  An arbitrary cut-off level was 
set at 0.5 units to distinguish tumors that express higher levels of paralemmin (red dashed 
line).  Data are normalized to HPRT. ER positive tissue bars are red and lined. 
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Figure 3.2  Paralemmin expression in reduction mammoplasty tissue. 
Total RNA was isolated from tissue obtained from reduction mammoplasty and 
paralemmin mRNA expression was determined by qRT-PCR.  Samples were tested 
twice; SD represents variation between PCR runs.  Data are normalized to HPRT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 33 -  
Recipient Block Design 
 
 
 
 
 
 
 
 
 
Figure 3.3  Recipient block design 
 
 
 
 
 
 
 
 Using 3 different tumor types (infiltrating ductile carcinomas (IDC), 
ductile carcinoma in situ (DCIS), reduction mammoplasty tissue 
unassociated with invasive carcinomas (RM)  
 35 to 72 cases of each type   
 2 TMAs made of 20 cases each for Reduction Mammoplasty 
 1 TMA made from 36 cases for DCIS 
 2 TMAs made from 36 cases each for IDC 
 3 punches from each tumor   
 63 to 108 punches in each paraffin block 
 punches are 1.000mm diameter 
 distance between punches = 2.000mm 
 TMAs constructed using the Beecher Instruments, Inc. Manual Tissue 
Arrayer (MTA-1) 
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Tissue Microarray Construction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4   Constructing tissue microarrays 
Five tissue microarrays were constructed to investigate paralemmin’s expression and 
localization in tissue from reduction mammoplasty, infiltrating ductile carcinoma and 
ductile carcinoma in-situ. First, a recipient block is made from paraffin wax and cores are 
punched out in a designed pattern. An area of interest is marked on H&E slide by a 
pathologist, this area is then matched up to the donor block (from which it has been 
sliced) and a punch is taken from the marked area, then the core is inserted into the 
recipient block. 
 
H&E Stained slide 
Donor Block 
Recipient Block 
Removing Core from Donor Block 
Inserting Core 
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Comparing Paralemmin Staining Among RM, DCIS and IDC TMAs 
 
 
 
 
 
 
 
 
 
 
Table 3.1  Comparing paralemmin staining among RM, DCIS and IDC TMAs. 
All TMAs were scored and given values of 0, 1+, 2+ or 3+. The highest value given 
among the three punches for each case was used, and divided into either “Weak” (0 or 
1+) or “Strong” (2+ or 3+). The totals of each were inserted into the table for each type of 
TMA constructed. 
 
 
 
 
 
 
 
 
 
 
Paralemmin Staining 
  RM DCIS IDC 
Weak 29 7 20 
Strong 11 24 45 
 - 36 -  
Comparing Paralemmin Staining to Tumor Grade 
                                                                                                                             A                                                                                                       
Paralemmin Staining to Tumor Grade (DCIS-6) 
  I II III 
Weak 2 5 2 
Strong 6 9 10 
 
                  B  
 
 
 
 
 
 
 
 
 
 
 
Table 3.2  Comparing paralemmin staining to tumor grade. 
All TMAs were scored and given values of 0, 1+, 2+ or 3+. The highest value given 
among the three punches for each case was used, and divided into either “Weak” (0 or 
1+) or “Strong” (2+ or 3+). These values were then assigned to tumor grades I, II or III 
and inserted into each table. For the 5 DCIS only cases I called LG as I, LIG/IG as II and 
IHG/HG as III. Only the in-situ component of each DCIS case was counted in the 
evaluation of A, and only the invasive components were counted in the evaluation of B. 
 
 
 
Paralemmin Staining to Tumor Grade (IDC-4 &7) 
  I II III 
Weak 6 5 11 
Strong 7 15 22 
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Comparing Paralemmin Staining to ER. PR and HER-2 Status 
 
 
Table 3.3  Comparing paralemmin staining to ER, PR and HER-2 status. 
All TMAs were scored and given values of 0, 1+, 2+ or 3+. The highest value given 
among the three punches for each case was used, and divided into either “Weak” (0 or 
1+) or “Strong” (2+ or 3+). These values were then assigned to each ER/PR/HER-2 
positive or negative case and inserted into the table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paralemmin Staining to ER, PR, HER-2 
  ER PR HER-2 
  pos neg pos neg pos neg 
Weak 21 8 16 12 7 20 
Strong 60 6 54 13 17 47 
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CHAPTER 4 
PARALEMMIN'S EXON-DELETED SPLICE VARIANTS IN HUMAN BREAST 
CELL LINES, HUMAN BREAST TUMOR TISSUE AND REDUCTION 
MAMMOPLASTY TISSUE 
Introduction 
 
Commonly in cells, introns are spliced out of pre-mRNA leaving only the exons to go 
through translation into proteins. One of the mechanisms that cells have to produce a 
diversity of proteins from existing proteins is through splicing of not only the introns, but 
also one or multiple exons. Previous studies have shown that paralemmin has multiple 
exon-deleted splice variants in various tissues and cell types (Kutzleb et al. 1998). 
Specifically, exons 7 and 8 have been shown to be spliced out in chicken tissues and exon 
8 has been shown to be spliced out in human tissues. From our examination of 
paralemmin’s protein expression among breast cancer and immortalized, normal breast 
cells we see that there are multiple bands on Western Blots. One of the known causes of 
this electrophoretic heterogeneity is alternative splicing of the mRNA. Because of this, 
we thought it important to look for paralemmin splice variants among breast cell lines, 
tumor tissue and tissue from reduction mammoplasty. Since we are the first to identify 
paralemmin in breast cancer tissue, nothing is known of the occurrence and distribution 
of its splice variants in the breast. Splice variants of paralemmin may perform different 
functions and play a role in the progression of beast cancer. 
 
Primers were designed to detect exon-deleted splice variants in paralemmin mRNA. RNA 
isolated from five breast cancer cell lines and four immortalized, normal cell lines were 
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examined using real time RT-PCR to determine which exons, if any, were spliced out of 
the mRNA.  Seven primer sets were designed with sense primers complimentary to 
sequences in exons 1, 2, 3, 4, 5, 6 and 7 and their antisense primers complimentary to 
sequences in exons 3, 4, 5, 6, 7, 8 and 9 respectively.  This design left a one-exon gap 
between each primer set, and allowed determination of the presence or absence of the 
center exon when visualized by gel electrophoresis.  Table 4.1 and Figure 4.1 give visual 
representations of primer design methodology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 40 -  
Materials and Methods 
 
Cell Culture and RNA Purification 
Methods are the same as presented in Chapter 2. 
 
Human Tissue Specimens 
Institutional Review Board approval for this study was obtained from Baystate Medical 
Center. Thirty frozen breast tumors, (from Gozgit et al. 2006), were retrieved from 
Baystate Medical Center, Department of Surgical Pathology and were identified 
numerically, maintaining patient anonymity. Breast carcinoma specimens were sectioned 
to ≤0.5 cm in thickness and immediately placed in pre-chilled RNA Later-Ice (Ambion, 
Austin, TX) for 24 hours. Tissues (20-30 mg) were homogenized and RNA was isolated 
using the Qiagen RNeasy Fibrous Tissue kit (Qiagen) (Gozgit et al. 2006).  Reduction 
Mammoplasty RNA (n=11) was a generous gift from Dr. Sallie Smith-Schneider 
(Pioneer Valley Life Science Institute, Springfield, MA). 
 
RT-PCR 
RNA samples were amplified using the One-Step RT-PCR kit (Qiagen) in the MJ 
Research PTC-200 gradient thermal cycler. Total RNA (75 ng) was incubated with 
Qiagen RT-PCR master mix including primers (10 µmol/L each), substituting the SYBR 
Green with RNase-free water. After the reverse transcription step (50°C for 30 min) and 
the step to activate the HotStar Taq DNA polymerase and simultaneously inactivate the 
reverse transcriptase (95°C for 15 min), the PCR was run 45 cycles of 95°C for 15 s, 
60°C for 15 s, and 72°C for 30 s; and 72°C for 5 min for final extension. The components 
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of the PCR products were separated by electrophoresis on a 2.0% low melting point 
agarose gel and visualized with ethidium bromide.  Paralemmin’s (NM_002579) exon-
specific primers were designed using Primer3, and checked for extendible primer dimers 
using PerlPrimer (Table 4.1). 
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Results and Discussion 
Splice Variants Found in Breast Cell Lines 
Five breast cancer cell lines (TMX2-28, MCF-7, MDA-MB-231, T47D and ZR-75-1) and 
four immortalized and finite lifespan “normal” breast cell lines (MCF-10A, 184, 184A1 
and 184AA2) were subjected to RT-PCR analysis, using specific primer sets (Table 4.1 
and Figure 4.1) designed to detect paralemmin’s exon deleted splice variants.  The first 
two primer sets tested, primer sets 2 and 3, which were made to detect deletion of exons 2 
and 3, showed many non-specific bands when analyzed by gel electrophoresis (data in 
appendix). The TMX2-28 cell line was the only to one to show any expected products 
using primer set 2, which was the full length product at 294bp, although it also showed a 
product larger than any expected at ~425bp. All other cell lines showed products that 
were smaller than any expected with some of the products being possible primer dimers 
at ~60bp to ~70bp. Similar to the results from primer set 2, there were many non-specific 
products from primer set 3, although all but the 184 cell line produced the full length 
product (data in appendix). It was reasoned that the high GC content of the 5’ end of the 
gene accounted for the non-specific binding of the first two primer sets, and accounted 
for the unexpected products. These two primer sets were not used in any following 
analysis because they did not produce useful data, and the amount of breast tissue RNA 
was limited.  
 
Primer sets 4 through 7 resulted in strong full length bands, but no smaller products, 
indicating that no splice variants were detected. Primer set 8, which detected deletion of 
exon 8, was the only primer set to produce both the large and small products, indicating 
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an exon 8 splice variant in all cell lines tested. The presence of the large and small 
products indicate that at least two forms of paralemmin are present in the cell lines tested; 
one full length paralemmin and one without exon 8 (Figure 4.2, 8). 
 
Splice Variants Found in Breast Tumor Tissue 
RNA from 30 breast tumor tissues was analyzed using primer sets 4 through 8 to detect 
exon-deleted splice variants in paralemmin (Figure 4.3). Four normal tissue samples (T-
31 to T-34) were also analyzed. Similar to the analysis of the cellular RNA, all the tumor 
samples analyzed displayed the full length product and the exon 8 splice variant when 
using primer set 8. Only one other exon-deleted splice variant was detected and that was 
an exon 6 splice variant in tumor sample T-2.   
 
Splice Variants Found in Reduction Mammoplast Tissue 
RNA from five reduction mammoplast tissue samples was analyzed using primer sets 4 
through 8 to detect exon deleted splice variants in paralemmin (Figure 4.4, 4 through 8). 
When performing RT-PCR using primer sets 4 through 7, only the large product was 
visualized indicating that no splice variants exist in exons 4 through 7 of the samples 
tested. In contrast to the cell lines and tumor tissue, an exon 8 splice variant was not 
detected in RNA from reduction mammoplasty tissue; only very weak bands at the 
smaller expected product length were seen in three of the five samples. After this initial 
discovery, six additional reduction mammoplasty tissue RNA samples were obtained and 
tested for the exon-8-splice variant. As can be seen in Figure 4.4, only one of the eleven 
samples tested shows a faint band at the expected product length for an exon 8 splice 
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variant. The lack of the exon-8-splice variant in reduction mammoplasty RNA is 
interesting as all of the breast cell lines and breast cancers expressed the variant, 
suggesting that the exon-8-splice variant could be specific to breast cancer. 
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Conclusion 
In this chapter, the question of whether exon deleted splice variants of paralemmin were 
expressed in a subset of breast cancer and normal and immortalized breast cell lines, 
breast tumor tissue and tissue from reduction mammoplasty was asked. To answer this 
question, primer sets were designed, to detect the possible deletion of each internal exon 
(2 through 8), and used in RT-PCR analysis of the specified RNA samples. Running the 
PCR products on a gel would then reveal, by which products were amplified, if any exon 
deleted splice variants existed. The exon 8 splice variant was found to be the most 
common variant, and was found in all samples tested except in reduction mammoplast 
RNA. It should be noted that reduction mammoplast tissue is different from both cell 
lines and tumor tissue in that it has a major fatty tissue component that could be affecting 
the results. While there are a higher proportion of epithelial cells in tumor tissue, and 
certainly in cell lines, this is not the case for reduction mammoplasty tissue, which is 
mainly not epithelial. This could be an alternate explanation as to why the exon 8 splice 
variant was not detected in reduction mammoplasty tissue. The only other splice variant 
detected was that of exon 6 in tumor sample T-2. A breakdown of exon-deleted splice 
variants in paralemmin can be seen in Table 4.2. The deletion of exon 8 could change the 
function of the protein in that the amino acids which correlate to exon 8 have been 
previously shown to possess binding affinities with the D3 dopamine receptor in 
hippocampus and cerebellum and in glial and neuronal cultures (Basile et al. 2005). The 
possible function as a binding partner for other membrane or cytosolic proteins in breast 
cancer, and the possible role of exon 8 in this binding should be further explored. 
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Primers to Detect Exon-Deleted Splice Variants in Paralemmin 
    Primer Sequence Nucleotide 
Expected Product 
Lengths 
PS-
2 sense CCCGGACAATAAACAGCAG 10 
  antisense GCGCTTGTTCTCGATCTCC 304 
294bp = full product     
242bp = -exon 2 product 
PS-
3 sense AGAGACCACGTCCCAGCAG 226 
  antisense GCATCTGCCTCCTCAGGTC 431 
205bp = full product     
124bp = -exon 3 product 
PS-
4 sense AGGCGGAGATCGAGAACAAG  282 
  antisense CCAGCACCTCAATTTCCTTC  503 
221bp = full product     
90bp   = -exon 4 product 
PS-
5 sense CAGGACGACGAGCAGAAGA 431 
  antisense GGAGACTCGCTTGTCTTTGG 664 
233bp = full product     
82bp   = -exon 5 product 
PS-
6 sense AAGGAAATTGAGGTGCTGGA 485 
  antisense CGTGTTGGAGACTCGCTTG  670 
185bp = full product     
163bp = -exon 6 product 
PS-
7 sense TGATGAATTCACAGCAGACG  612 
  antisense GTCTCCCCTGTCACCTTGTC  762 
150bp = full product     
90bp   = -exon 7 product 
PS-
8 sense ACAAGCGAGTCTCCAACACG  651 
  antisense CCGCTTTGTGGATGAGTTC  926 
275bp = full product     
143bp = -exon 8 product 
 
 
Table 4.1  Primers to detect paralemmin’s exon deleted splice variants. 
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Figure 4.1  Methodology for detecting paralemmin’s exon-deleted splice variants 
using specific primer sets. 
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RT-PCR Analysis of Cell Line RNA 
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Figure 4.2  Paralemmin’s exon deleted splice variants in breast cell lines. 
Cell cultures were grown to sub-confluence; total RNA was isolated and subjected to RT-
PCR analysis.  PCR products were run on a 2% low melting agarose gel and visualized 
by ethidium bromide.  Lanes 1 through 11 are TMX2-28, MCF-7, MDA-MB-231, MCF-
10A, 184, 184A1, 184AA2, water control, T47D, ZR-75-1 and water control 
respectively. The numbers 2 through 8 represent the primer sets to detect splice variants 
of exons 2 through 8 respectively.  Numbers on the left represent full length product (top 
number) and product minus central exon (bottom number). 
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RT-PCR Analysis of Frozen Tumor Tissue 
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RT-PCR Analysis of Frozen Tumor Tissue 
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Figure 4.3  Paralemmin’s exon deleted splice variant patterns in breast tumor tissue. 
Total RNA was isolated and subjected to RT-PCR analysis.  PCR products were run on a 
2% low melting agarose gel and visualized by ethidium bromide.  Numbers above figures 
represent tumor ID numbers.  Numbers 4 through 8 represents primer sets to detect splice 
variants of exons 4 through 8 respectively.  Numbers on the left represent full length 
product (top number) and product minus central exon (bottom number). 
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RT-PCR Analysis of Reduction Mammoplast Tissue 
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Figure 4.4  Paralemmin’s exon deleted splice variant patterns in reduction 
mammoplast tissue. 
Total RNA was isolated and subjected to RT-PCR analysis.  PCR products were run on a 
2% low melting agarose gel and visualized by ethidium bromide.  Numbers above figures 
represent sample ID numbers.  Numbers 4 through 8 represents primer sets to detect 
splice variants of exons 4 through 8 respectively.  Numbers on the left represent full 
length product (top number) and product minus central exon (bottom number). 
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Paralemmin Exon-Deleted Splice Variants 
    Exon 8 Splice Variant Exon 6 Variant 
    ∆8 wt Weak ∆6 wt 
Cancer 4 0 1 0 5 
Ce
ll 
Li
n
es
 
Normal 4 0 1 0 5 
Frozen Breast 
Tumor Tissue 24 0 0 1 23 
Reduction 
Mammoplasty 0 9 1 0 10 
 
 
Table 4.2  Breakdown of paralemmin’s exon-deleted splice variants 
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CHAPTER 5 
CONCLUSION AND FUTURE STUDIES 
Paralemmin is a membrane protein associated with the cytosolic side of the plasma 
membrane through the addition of fatty acid chains by prenylation and di-palmitoylation 
at its COOH terminal end, and is thought to be associated with lipid rafts. Paralemmin 
protein concentrates at sites of cellular expansion and process formation, and when 
overexpressed, causes spikes to form and cells to expand. Kutzleb and colleagues also 
showed that paralemmin is differentially spliced in a tissue specific and developmentally 
regulated manor. Similarly, a study by Arstikaitis et al. (2008) reported that paralemmin 
is a modulator of filopodia induction and is required for dendritic spine maturation, and 
that knockdown of paralemmin in developing neurons reduces the number of filopodia 
and spines formed and diminishes the effects of Shank1b on the transformation of 
existing filopodia into spines. Basile and colleagues (2005) reported that amino acids 
154-230 of paralemmin strongly interact with the third intracellular loop of the D3 
dopamine receptor. As has been described by Kutzleb (1998) and in this study, exon 8 is 
the most common of the splice variants, which removes the nucleotides that correspond 
to amino acids 154-230, and therefore removes the ability to bind to this receptor. These 
studies point to multiple functions for paralemmin, depending on the presence or absence 
of exon 8. Further study is warranted to determine if new functional domains arise from 
the splicing out of exon 8, and to determine if there are other molecules which bind to 
paralemmin. 
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In chapter 2 we have shown that paralemmin mRNA is differentially expressed among 
several breast cancer and non-tumorigenic cell lines. When comparing expression levels 
to cell line characteristics such as invasiveness, ER status and origin of cells, no clear 
correlations can be made. What we did find was that paralemmin was very lowly 
expressed in the non-tumorigenic cell lines compared to cancer cell lines. The lower 
expression in the non-tumorigenic cell lines suggests that paralemmin could be a 
diagnostic biomarker for a subset of breast carcinomas. In the same chapter, paralemmin 
protein expression was examined by Western Blot analysis. Contrary to the large 
difference seen between TMX2-28 and MCF-7 mRNA expression, paralemmin protein 
levels between these two cell lines were nearly identical (Figure 2.4). Another conflicting 
result was the difference between the MDA-MB-231 cell line paralemmin mRNA and 
protein expression, which revealed mRNA expression to be relatively high, while the 
protein expression was lower than anticipated. The ZR-75-1 expression for paralemmin 
was highest in both mRNA and protein. When evaluating the band at 35kDa, it was 
noticed that this band exactly lined up with a band present when using the control pre-
immune serum. For this reason, we dismissed this band as a non-specific interaction.  
 
In the next chapter we evaluated paralemmin expression and localization, in tumor tissue 
and tissue from reduction mammoplasty, by qRT-PCR and tissue microarray analysis. Of 
the 26 samples in which RNA was analyzed, 14 showed high levels of paralemmin 
expression, and of those 14, 12 (86%) were ER-pos. When observing paralemmin 
expression in reduction mammoplasty tissue samples, we see variable expression among 
the samples. When comparing tumor and reduction mammoplasty tissue for paralemmin 
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mRNA expression, reduction mammoplasty expression is on average ten times higher 
that tumor tissue expression. In a previous study, Tripathi et al. (2007) compared RNA 
from reduction mammoplasty tissue to that of tumor tissue and normal tissue surrounding 
tumor tissue by cDNA microarray analysis, and did not report paralemmin as one of the 
genes differentially expressed between tumor and reduction mammoplasty tissues. It 
would be interesting to further investigate the differences in gene expression among 
“normal” and diseased tissue to give insight into changes that occur in disease 
progression. When examining the localization of paralemmin in tissue microarrays 
(TMAs) made of reduction mammoplasty (RM), ductile carcinoma in-situ (DCIS) and 
infiltrating ductile carcinoma (IDC) tissue, we observed that it is highly associated with 
the plasma membrane, which is consistent with previous reports on paralemmin 
localization in other tissues and species (Arstikaitis et al. 2008, Kutzleb et al. 2006 and 
1998, Bagchi et al. 2003 and El-Husseini et al. 2001). We also used these TMAs to 
investigate whether there was any correlation between paralemmin staining and the type 
of tissue, the grade of the tumor and the ER, PR and HER-2 status of the tumor tissues 
examined. The obvious difference we first observed was that of the staining between RM 
and DCIS/IDC tissues. A higher percentage of the RM cases examined expressed low 
levels of paralemmin while a higher percentage of the DCIS and IDC cases expressed 
high levels of paralemmin (Table 3.1). This result is inconsistent with the qRT-PCR data 
where higher levels of paralemmin expression are observed in RM tissue RNA, although 
this result is in agreement with the qRT-PCR analysis of the non-tumorigenic 184 cell 
lines analyzed, which were derived from reduction mammoplasty. It is possible that the 
specific tissues analyzed by each assay differ, in that analysis by TMA and 
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immunohistochemistry is primarily concentrated on epithelial cell staining while analysis 
by qRT-PCR uses RNA from all cell types in the tissue specimen which consists of 
epithelial cells, fibroblasts, immune cells and adipose tissue. Another pattern emerged 
when comparing paralemmin staining to tumor grade. As tumors progress from stage I to 
stage III, a higher percentage of cases stain strong for paralemmin for both DCIS and 
IDC TMAs (Table 3.2A, B). The final observation made in chapter 3 was that of 
paralemmin expression and hormone receptor (ER, PR) and HER-2 status. For the ER 
positive, PR positive and HER-2 positive and negative cases, we observed similar ratios 
of weak to strong paralemmin staining as observed in total DCIS and IDC cases. What 
was interesting were the ER and PR negative cases examined, which in the PR negative 
cases weak and strong staining become almost equal and in the ER negative cases a shift 
to a higher percentage of weakly stained cases is observed. This is similar to the RM 
TMA where a higher percentage of cases were scored as weak for paralemmin 
expression. As normal breast tissue is known to not express the ER, this observation is 
not surprising. 
 
In chapter 4, the goal was to examine cell line, tumor tissue and reduction mammoplasty 
tissue mRNA for any paralemmin exon-deleted splice variants using specifically 
designed primer sets (Table 4.1). As a previous report by Kutzleb (1998) revealed that 
paralemmin splice variants exist in other tissues and cell types, we thought it would be 
interesting to examine breast cell line and tissue mRNA for any such splice variants. In 
all of the tissues and cell types tested, the deletion of exon 8 was found in all but one type 
of tissue. This result was observed by the presence of two bands visualized on an agarose 
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gel, indicating the presence of both a full length product and a smaller product lacking 
exon 8 (Figure 4.2, and 4.3).  Interestingly, reduction mammoplasty tissue either did not 
express the exon 8 splice variant or expressed it in very low numbers (Figure 4.4). One 
interesting relationship exists between exon 8 of paralemmin and the D3 dopamine 
receptor (Basile et al. 2005), where they have been shown to bind each other. Deletion of 
this exon may contribute to different binding sites emerging and possibly different roles 
for expressed protein. The deletion of exon 6 was also observed in tumor sample T-2 
(Figure 4.3), which is the smallest of the exons, but no known function for this exon is 
presently known. 
 
As paralemmin has been shown to be highly membranous, associated with lipid rafts and 
concentrated at sites of cell expansion and process formation (Arstikaitis et al. 2008, 
Kutzleb et al. 2006 and 1998, Bagchi et al. 2003 and El-Husseini et al. 2001), further 
investigation is warranted into paralemmin’s possible role in cancer cell invasion and 
metastasis. This can be achieved by observations made after over expressing paralemmin 
or knocking down paralemmin expression in cancer cell lines known to be non-invasive 
and invasive respectively. Also, very little is known about interactions between 
paralemmin and other proteins or molecules, and such knowledge would be highly useful 
for any further analysis into a possible function in breast cancer. 
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APPENDIX A 
 
TMA SCORE SHEETS 
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APPENDIX B 
 
PRIMER SETS 2 AND 3 NON-SPECIFIC PRODUCTS 
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